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Dental lesions represent about 1% of oral cavity tumors being ameloblastoma the most common 
one. It is a tumor of epithelial origin that mainly affects the jaw, and less commonly the maxilla. Its 
clinical presentation is that of an asymptomatic slow-growing tumor. Despite being a benign tumor, 
it has an invasive behavior with a high rate of recurrence if not treated properly.
Objective: To describe the cases of ameloblastoma in a reference department.
Methods: Retrospective analysis of 40 cases. The variables analyzed were: age, gender, ethnicity, 
tumor location, type of treatment, complications and recurrence.
Results: The most affected gender was male - 21 cases (52.5%); with a predominance of Caucasians 
- 24 cases (60%). The mean age was 35.45 years; the most common location was in the jaw - 37 cases 
(92.5%). Facial asymmetry was the most frequent complaint. Of the 40 cases, 33 were submitted to 
surgery. Of those submitted to surgery, 24 (72.72%) underwent segmental resection, with recurrence 
in 4 (12.12%) cases.
Conclusion: Ameloblastoma may relapse when treatment is not performed with broad surgical 
resection of the lesion with wide safety margins.
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INTRODUCTION
Ameloblastoma is a benign neoplasia which can 
be locally invasive. Among odontogenic neoplasia, the 
ameloblastoma affects the bones of the maxillomandibular 
complex, representing the odontogenic tumor of higher 
clinical significance1. The term ameloblastoma was first uti-
lized in 1930, when an odontogenic tumor was described 
with multiple cords and interconnected cell laminas, of 
epithelial origin and homologous with the dentogingival 
lamina of onset during odontogenesis2. It may originate 
from remains of the dental lamina, reduced epithelium 
from the enamel, epithelial remains of Malassez or from 
the basal cells of the surface epithelium3,4.
The classification of this neoplasia, by the World 
Health Organization (WHO), places it as a tumor stem-
ming from the odontogenic epithelium without ectome-
senchima5.
The ameloblastoma has a relatively low incidence, 
encompassing only 1% of all maxilla and mandible tumors, 
most of the cases being diagnosed between the third and 
fifth decades of life6. It is a slow growth tumor, with only 
few symptoms in initial stages7. Despite being benign, it 
has an invasive behavior with a high rate of recurrence if 
not treated properly8.
The goal of the present paper is to do a descriptive 
review of ameloblastoma cases admitted in a reference 
head and neck cancer treatment center.
PATIENTS AND METHODS
The present study was approved by the Ethics in Re-
search Committee of the Institution where it was carried out.
We made a retrospective analysis of 40 charts, from 
patients diagnosed with ameloblastoma, between 1978 
and 2011. We assessed clinic-demographic and histopa-
thological characteristics of these cases. We analyzed the 
following variables: age, gender, ethnicity, tumor location, 
type of treatment, complications and recurrence. This study 
had a descriptive statistical analysis.
RESULTS
In this series, there were 21 (52.5%) cases that were 
males and 19 (47.5%) females. Twenty-four (60%) cases 
were Caucasians and 16 (40%) were non-Caucasians. The 
mean age was 35.45 years (ranging between 14 and 65).
The mandible was the most affected site. Nineteen 
(47.5%) patients had tumors restricted to the mandible body. 
Of these, five (12.5%) went beyond the mid-line. Eight (20%) 
had involvement of the mandible body and angle or angle 
and ramus; in 10 (25%) cases the lesion advanced to the 
body, angle, ramus and condyle; and three cases (7.5%) 
involved the maxilla - a less frequent location (Figure 1).
Facial asymmetry was the foremost complaint in 
65% (26 cases). Thirty-three (82.5%) patients were sub-
mitted to a surgical procedure. Of these, 24 (72.72%) 
were submitted to segment resection of the mandible; 
five (15.15%) to enucleation or curettage, one (3.03%) to 
marginal resection of the mandible and three (9.09%) to 
maxillectomy. The mandibular reconstruction, when indi-
cated, was carried out with the miniplate for mandibular 
reconstruction and/or iliac crest bone graft.
As far as surgical complications are concerned, there 
were wound infections in eight (24.24%) patients. Tumor 
recurrence in four cases (12.12%), three (9.09%) after curet-
tage and in one (3.03%) it happened after maxillectomy. 
Of the three (9.09%) patients who had a recurrence after 
curettage, two (6.06) were plexiform and one (3.03%), 
unicystic (Figure 2).
Figure 1. Recurrence of maxilla ameloblastoma.
Figure 2. Plexiform pattern ameloblastoma, showing the cystic-type 
degeneration. HE 100x.
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DISCUSSION
Gender distribution was pretty much the same, 
52.5% men and 47.5% women, which is agreement with 
data described in the literature9. In our study, there was a 
predominance of Caucasians - 60% of the cases.
The diagnosis of ameloblastoma can be obtained by 
means of a panoramic x-rays done in dental care routine, 
showing intraosseous growth or, in more advanced cases, 
with expansion of the bone cortical, determining facial 
asymmetry - which was the most common complaint in 
our series. We stress that most of these cases had already 
been treated.
As far as location is concerned, the mandible was 
the most frequent site, with 92.5%; three (7.5%) patients 
had a maxilla tumor. The incidence of ameloblastoma, as 
to anatomical location, is almost exclusive in the mandible, 
happening in 80% to 97% of the cases. Its occurrence in the 
maxilla is rare, varying between 3% and 13%4,10. According 
to the literature, in the maxilla, 47% of the cases are in 
the posterior region and 15% in the maxillary sinus and 
nasal cavity floor11,12. There is no gender predilection. In 
our experience, two cases were posterior and one case, 
treated anteriorly, affected both maxillary sinuses. Ame-
loblastoma rarity in the maxilla may cause diagnosis and 
treatment difficulties13.
There is no standardization in the literature as to 
mandible regions affected. Lunardi et al.8 suggest division 
in anatomical areas and not in dental regions, as per des-
cribed by Reichart et al.9.
Since we are a reference center for cancer treatment, 
and ameloblastoma is a benign tumor, the cases referred 
were either advanced, with large facial deformities and 
complex resections, or had been submitted to some type 
of previous treatment, unsuccessfully.
In our series, 20 (50%) patients had already been 
submitted to some type of surgery. Ten cases (25%) 
had extensive lesions which involved the mandible 
body, angle, ramus and condyle, besides five cases 
(12.5%) of body involvement which went beyond 
the midline, and one case (2.5%) of bilateral maxilla 
involvement, making up a total of 16 (40%) cases of ex-
tensive lesions.
There are numerous methods for treatment, in-
cluding enucleation and/or curettage, marginal en-block 
resection or hemiressection (hemimaxillectomy or hemi-
mandibulectomy), cryotherapy, radiotherapy, and surgery 
- the most indicated treatment approach. The choice of 
treatment depends on lesion size, type, location and ge-
neral patient condition. In this study, 24 (72.72%) were 
submitted to segment resection, five (15.15%) cases sub-
mitted to enucleation or curettage, one (3.03%) to margi-
nal resection and three (9.09%) to maxillectomy. Surgery 
is the only treatment for ameloblastoma, because of its 
resistance to radiotherapy14. After segment resection, it is 
essential to rebuild it, with bone graft and/or a titanium 
plate and screws15.
Insofar as surgical complications are concerned, 
there was wound infection in eight (24.24%) patients, with 
the need for antibiotic treatment, of whom two had bone 
graft loss. Four (12.12%) patients had recurrences, three 
(9.09%) after curettage and one (3.03%) after maxillectomy.
Treatment of the cases investigated in this study was 
carried out only after biopsy results indicated ameloblasto-
ma. Not specifying the histological type – and because of 
that we used the histological reclassification15, which is of 
the utmost importance because of the behavior of the most 
common types (follicular, plexiform and unicystic) which 
presented and influence treatment9. For the plexiform and 
follicular types, radical surgery is the best procedure, with 
a safety margin of 1.5 and 3.0 cm and, for the unicystic 
type, bone curettage is indicated16.
The bilateral maxillectomy recurrence happened to 
one patient coming from another clinic, with a prior his-
tory (five years before) of the maxilla follicular variant of 
ameloblastoma. In our service, the lesion was 15cm long 
in its longest axis, occupying the entire facial structure, 
from the orbit floor all the way to the hard palate, in the 
craniocaudal direction and from the nasal cavities to the 
rhinopharynx, in the anteroposterior direction.
CONCLUSION
The ameloblastoma is usually of late diagnosis be-
cause of its poor symptomatology and low prevalence. In 
our experience, curettage did not prove to be an efficient 
treatment. Its treatment requires, preferably for advanced 
tumors, the resection with safety margins and immediate 
reconstruction whenever possible. There is a need for a 
routine histological classification of the ameloblastoma 
for its morphological characterization and, thus, a better 
treatment definition. Nonetheless, the main success factor 
associated with the treatment is the early diagnosis and 
the first efficient and preferable treatment in specialized 
services.
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